Revumenib in Patients With Myelofibrosis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Revumenib
Related studies linked through entity extraction aliases.
Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Menin-Inhibitor Targeted Maintenance in AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Revumenib and Mezigdomide in People With Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Status
- RECRUITING
- Phase
- PHASE3
A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients
- Status
- WITHDRAWN
- Phase
- PHASE1
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- Status
- RECRUITING
- Phase
- PHASE3
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1
Revumenib in Combination With 7+3 + Midostaurin in AML
- Status
- RECRUITING
- Phase
- PHASE1
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
- Status
- RECRUITING
- Phase
- PHASE2
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- Status
- RECRUITING
- Phase
- PHASE1
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Expanded Access Program for Revumenib
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2